BioAtla (BCAB) Non-Current Debt (2020 - 2021)

BioAtla's (BCAB) quarterly Non-Current Debt came in at $682000.0 in Q2 2021, little changed quarter-over-quarter from $682000.0 in Q1 2021.

BioAtla (BCAB) Non-Current Debt (2020 - 2021) Analysis & Trends

BioAtla's Non-Current Debt history runs 2 years deep, the most recent figure standing at $682000.0 for Q2 2021.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $682000.0 in Q2 2021; TTM through Jun 2021 was $682000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $682000.0, changed N/A from the prior year.
Non-Current Debt steadied at $682000.0 in Q2 2021 per BCAB's latest filing, from $682000.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $682000.0 in Q4 2020 and bottomed at $682000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	BioAtla	5.74 Mn	5.74 Mn	-	-

Download Data